This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.
Eligibility
Sex
ALL
Min age
50 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Adult patients between 50 and 75 years old
* Subjects at intermediate to high risk for ASCVD
* Asymptomatic patients without cardiac chest pain
* Evidence of atherosclerosis on baseline CCTA
Exclusion Criteria:
* Renal insufficiency, defined as eGFR \< 30 ml/min
* History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke)
* Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy
* Change in lipid lowering therapy in the last 6 months
* Use of more than two antihypertensive agents
* No coronary atherosclerosis at baseline imaging
* Active malignancy requiring treatment
* Atrial fibrillation
* Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
* Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Primary outcome measure(s)
Coronary Artery Disease Progression — Through study completion, between 130-156 weeks
Trial sites (1)
Facility
City
Region
Status
Amsterdam UMC, location AMC
Amsterdam
Netherlands
More Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.